{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:17:11Z","timestamp":1774325831032,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.ejca.2012.06.023","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T20:20:25Z","timestamp":1343161225000},"page":"3456-3464","source":"Crossref","is-referenced-by-count":52,"title":["Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma \u2013 A phase II trial of the childhood liver tumour strategy group (SIOPEL)"],"prefix":"10.1016","volume":"48","author":[{"given":"J\u00f3zsef","family":"Zs\u00edros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Brugi\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Roebuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Maibach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Child","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Morland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz de","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind","family":"Ronghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Plaschkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Czauderna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Perilongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.06.023_b0005","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2000.18.22.3819","article-title":"Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach \u2013 results of the first prospective study of the International Society of Pediatric Oncology","volume":"18","author":"Pritchard","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/cncr.10632","article-title":"Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94","volume":"95","author":"Fuchs","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.06.023_b0015","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1200\/JCO.2002.07.400","article-title":"Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study","volume":"20","author":"Katzenstein","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0020","first-page":"53","article-title":"High dose chemotherapy does not improve the overall survival of children with hepatoblastoma","volume":"51","author":"Haberle","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2012.06.023_b0025","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.06.023_b0030","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study","volume":"28","author":"Zs\u00edros","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0035","unstructured":"Perilongo G, Zsiros J. Childhood liver tumours. In: Stevens MCG, Caron HN, Biondi A, editors. Cancer in children. Oxford: Oxford University Press; 2011."},{"key":"10.1016\/j.ejca.2012.06.023_b0040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-2008-1043805","article-title":"Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94","volume":"211","author":"Fuchs","year":"1999","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.ejca.2012.06.023_b0045","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00383-002-0906-0","article-title":"Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma","volume":"19","author":"Matsunaga","year":"2003","journal-title":"Pediatr Surg Int"},{"key":"10.1016\/j.ejca.2012.06.023_b0050","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.ejca.2004.01.042","article-title":"Phase II study of high-dose cyclophosphamide in relapsing and\/or resistant hepatoblastoma in children: a study from the SIOPEL group","volume":"40","author":"Cacciavillano","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2012.06.023_b0055","first-page":"746","article-title":"Relapses in hepatoblastoma patients: clinical characteristics and outcome: experience of the International Childhood Liver Tumour strategy Group \u2013 SIOPEL","volume":"53","author":"Semerano","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2012.06.023_b0060","series-title":"Pediatric liver tumors","first-page":"34","article-title":"Salvage strategies","author":"Zs\u00edros","year":"2011"},{"key":"10.1016\/j.ejca.2012.06.023_b0065","first-page":"423","article-title":"Efficacy of systemic administration of Irinotecan against neuroblastoma xenografts","volume":"3","author":"Thompson","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.06.023_b0070","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1200\/JCO.1999.17.6.1815","article-title":"Direct translation of a protracted Irinotecan schedule from a xenograft model to a phase I trial in children","volume":"17","author":"Furman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00043426-200202000-00009","article-title":"Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience","volume":"24","author":"Cosetti","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00043426-200202000-00007","article-title":"Phase I study of irinotecan in pediatric patients with malignant solid tumors","volume":"24","author":"Mugishima","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/08880010500457152","article-title":"Irinotecan for children with relapsed solid tumors","volume":"23","author":"Shitara","year":"2006","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0090","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/neuonc\/4.2.102","article-title":"Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience","volume":"4","author":"Turner","year":"2002","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<156::AID-IJC24>3.0.CO;2-D","article-title":"Potent therapeutic activity of Irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice","volume":"73","author":"Vassal","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2012.06.023_b0100","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2003.08.175","article-title":"A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors","volume":"21","author":"Vassal","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0105","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.2006.06.1960","article-title":"Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children\u2019s Cancer Study Group","volume":"25","author":"Vassal","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0110","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ejca.2008.08.003","article-title":"A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)","volume":"44","author":"Vassal","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2012.06.023_b0115","first-page":"32","article-title":"A phase I study of Irinotecan in pediatric patients: a pediatric oncology group study","volume":"7","author":"Blaney","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.06.023_b0120","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1200\/JCO.2007.11.6103","article-title":"Phase II trial of irinotecan in children with refractory solid tumors: a Children\u2019s Oncology Group Study","volume":"25","author":"Bomgaars","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0125","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/0959-8049(96)00293-6","article-title":"Characterisation and clinical management of CPT-11 (Irinotecan)-induced adverse events: the European perspective","volume":"32","author":"Bleiberg","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2012.06.023_b0130","first-page":"S72","article-title":"Gastrointestinal toxicity of Irinotecan","volume":"12","author":"Hecht","year":"1998","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2012.06.023_b0135","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1200\/JCO.1998.16.7.2494","article-title":"Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study","volume":"16","author":"Langevin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0140","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S0959-8049(98)00229-9","article-title":"Camptothecins: a review of their development and schedules of administration","volume":"34","author":"O\u2019Leary","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2012.06.023_b0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2012.06.023_b0150","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1081\/BIP-100101181","article-title":"Multinomial phase II cancer trials incorporating response and early progression","volume":"9","author":"Zee","year":"1999","journal-title":"J Biopharma Stat"},{"key":"10.1016\/j.ejca.2012.06.023_b0155","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2001.19.3.785","article-title":"Application of a new multinomial phase II stopping rule using response and early progression","volume":"19","author":"Dent","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0160","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00043426-200212000-00014","article-title":"Novel therapeutic approaches in the treatment of children with hepatoblastoma","volume":"24","author":"Katzenstein","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/mpo.10300","article-title":"Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11)","volume":"41","author":"Palmer","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ejca.2012.06.023_b0170","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1399-3046.2006.00517.x","article-title":"Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan","volume":"10","author":"Ijichi","year":"2006","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.ejca.2012.06.023_b0175","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/pbc.22408","article-title":"Irinotecan as maintenance therapy in high-risk hepatoblastoma","volume":"54","author":"Qayed","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2012.06.023_b0180","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2006.07.1720","article-title":"Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children\u2019s Oncology Group","volume":"25","author":"Pappo","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912005266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912005266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T22:03:33Z","timestamp":1642889013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912005266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0959804912005266"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.06.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}